What are the fundraising trends in the neurotechnology market?

In our neurotechnology market deck, you will find everything you need to understand the market

This chart, featured in our neurotechnology market deck, breaks down revenue by customer segment in the neurotechnology market

Is more or less capital going into the neurotechnology market?

More capital is going into the neurotechnology market, both on the clean full-year comparison and on the freshest year-to-date comparison. Full-year disclosed equity funding rose from about $1.37B in 2024 to about $1.85B in 2025, a roughly 35% increase, and year-to-date 2026 funding reached about $1.39B by early July, compared with about $1.05B over the comparable period in 2025.

The conclusion is strong because both comparison windows point in the same direction. The full-year comparison says 2025 was larger than 2024, and the current-year comparison says 2026 was running ahead of the comparable 2025 period by early July.

But the neurotechnology market is not expanding evenly. In 2025, the largest deal represented about 35% of all disclosed capital, and the top three deals represented about 54%. In year-to-date 2026, the largest deal represented a lower 21% of capital, but the top three still represented about 55%.

The more careful reading is that headline capital is increasing, while ordinary non-megaround funding is not clearly improving. Capital excluding rounds above $50M was about $434M in 2024, about $398M in 2025, and only about $145M in year-to-date 2026, which means the market’s growth is being carried by large, high-conviction financings.

The practical takeaway is that the neurotechnology market is getting more money, but the money is not becoming easy. The largest checks are going to companies that look like platform-scale BCIs, clinically specific neuromodulation platforms, or strategic neural-interface infrastructure.

Is neurotechnology funding activity driven by more deals or larger rounds?

Neurotechnology funding activity is being driven by larger rounds in the full-year comparison, but by more deals and a stronger median round in the current-year comparison. Full-year deal count rose only slightly from 30 deals in 2024 to 31 deals in 2025, while total capital rose by about 35%, so the 2025 increase was mainly a round-size and concentration story.

The 2025 average round rose to about $60M from about $46M in 2024, but the median round fell to about $20M from about $24M. That combination matters because it shows that the top end got much bigger, while the typical company did not raise more.

Year-to-date 2026 looks different. By early July, the neurotechnology market had 22 qualifying deals, compared with 16 over the comparable period in 2025. Total capital rose from about $1.05B to about $1.39B, while median round size increased from about $18M to about $28M.

So the best answer is split by time frame: 2025 was mostly driven by larger top-end rounds, while 2026 so far is being helped by both more deals and a healthier median round. The caution is that capital excluding $50M+ rounds is lower in 2026 than it was over the comparable 2025 period, so the improvement is not broad across the whole funding ladder.

For more detail on deal sizes, medians, category splits, and round concentration, see the full neurotechnology market report.

Is neurotechnology capital moving toward later-stage or earlier-stage companies?

Neurotechnology capital is still mostly moving toward later-stage companies, but year-to-date 2026 has shown a meaningful early-stage rebound. In 2024, late-stage capital represented about 80% of disclosed funding, and in 2025 it again represented about 80%, which makes the longer-term structure clearly later-stage weighted.

The 2025 stage mix was especially late-stage heavy. Series D+ rounds alone captured about $990M, or roughly 54% of all capital, across only three deals. That means the biggest checks were going to companies perceived as technically validated, strategically important, clinically advanced, or closer to scale.

Year-to-date 2026 is more balanced. Late-stage Series B+ capital represented about $826M, or 59% of funding, while Seed, Series A, and Unknown-stage capital represented about $568M, or 41%. That is a much higher early-stage and unknown-stage share than the comparable 2025 period, when Seed through Series A represented only about 7% of capital.

The caveat is that early-stage capital in 2026 is inflated by unusually large early platform rounds. Merge Labs alone raised $252M at seed stage, which is not a normal seed benchmark for the neurotechnology market. The better interpretation is that capital is still structurally later-stage, but investors will write very large early checks when the company looks like a potential category-defining neural-interface platform.

This chart, featured in our neurotechnology market deck, compares the main business model options for neurotechnology device platforms

Is the neurotechnology market maturing or still experimental?

The neurotechnology market is maturing, but the frontier edge is still experimental. The clinical-device side of the neurotechnology market looks increasingly mature because large rounds are going into companies with clearer regulatory, clinical, reimbursement, or commercial paths. The BCI side remains more experimental, but it is where investors see the most platform upside.

The maturity signal is visible in the funding structure. Full-year funding rose from about $1.37B in 2024 to about $1.85B in 2025 without a major increase in deal count, and late-stage funding remained around 80% of total capital in both years. That is not what a purely experimental market looks like; it is what a selective scale-up market looks like.

At the same time, the market is not mature in the sense of being broad, liquid, or predictable. The top 10 deals captured 76% of 2024 capital, 81% of 2025 capital, and about 90% of year-to-date 2026 capital. That level of concentration shows that the neurotechnology market still depends on a small number of exceptional proof stories.

The practical distinction is important. Neuromodulation looks mature because it is built around specific indications such as pain, bladder dysfunction, migraine, tremor, Alzheimer’s disease, inflammatory disease, spinal cord injury, and other clinical needs. BCI looks less mature but more strategically explosive because investors are underwriting interface control, neural data, and long-term human-computer interaction potential.

Are new startups still entering the neurotechnology market?

Yes, new startups are still entering the neurotechnology market, and the 2026 signal is much stronger than the 2025 signal. In 2025, first financings represented only about 13% of deals and about 2% of capital, while in year-to-date 2026 first financings represented about 27% of deals and about 29% of capital.

This is a major shift from the full-year 2025 structure, when the market was overwhelmingly follow-on driven. The comparable 2025 period was especially weak for new entrants, with first financings representing only about 6% of deals and about 2% of capital.

The 2026 new-entrant signal is not broad and democratic, though. It is heavily shaped by a few unusually large early rounds in BCI, neuro-monitoring, and clinically specific neuromodulation. A $252M seed round should not be read as evidence that ordinary neurotechnology startups can raise unusually large seed rounds.

The better reading is that the neurotechnology market is still open to new startups, but only when they bring an unusually strong combination of modality defensibility, elite backers, clinical specificity, strategic relevance, or platform ambition. Generic neuro-adjacent software and wellness products remain much harder to fund at scale.

For the broader view of new company formation and first-financing activity in neurotechnology, see the neurotechnology market deck.

Are more investors entering the neurotechnology market?

Yes, more investors appear to be entering the neurotechnology market, especially in the current year so far. Full-year 2025 had about 111 unique disclosed investors, up from about 95 in 2024, and year-to-date 2026 already included at least 92 named investor entities or groups by early July.

The freshest comparison is even clearer. The comparable 2025 period had about 57 disclosed investors, while year-to-date 2026 had at least 92. Tier-1 investor participation also rose from about 17 over the comparable 2025 period to about 40 in year-to-date 2026.

The type of investor matters as much as the count. The neurotechnology market is attracting specialist medtech funds, crossover investors, strategic technology companies, public-sector strategic capital, and frontier technology backers. The presence of investors such as OpenAI, Bain Capital, Alibaba, Tencent, Samsung Next, Khosla Ventures, Lightspeed, Morningside, OrbiMed, and EIC Fund shows that neurotechnology is no longer being evaluated only as a medical-device niche.

The caution is that broader investor participation does not yet equal a dense specialist investor base. Repeat dealmaking remains limited, and many investors appear in only one qualifying deal. So the investor pool is broadening, but the market has not yet developed a stable club of repeat neurotechnology specialists.

This chart, featured in our neurotechnology market deck, shows annual funding in neurotechnology startups

Are top investors getting more or less active in neurotechnology?

Top investors are getting more visible in the neurotechnology market, but not necessarily more repeatedly active. The number of unique tier-1 investors rose from about 16 in 2024 to 31 in 2025, and year-to-date 2026 already showed around 40 tier-1 investors by early July.

That increase in marquee participation is meaningful. It suggests that leading venture firms, strategics, crossover investors, and major institutional backers are more willing to underwrite neurotechnology companies when the proof path or platform potential is strong enough.

But repeat activity is still thin. In 2024, only four named investors appeared in more than one qualifying deal. In 2025, five investors appeared more than once. In year-to-date 2026, only IAG Capital Partners is clearly identified as appearing in more than one qualifying disclosed deal.

The better interpretation is that top investors are not yet behaving like a dense, recurring specialist syndicate. Top-tier logos are entering the neurotechnology market around specific high-conviction companies, not spreading capital broadly across the category. A marquee investor in one round should be read as validation of that company, not automatic validation of the whole market.

Which neurotechnology subcategories are gaining momentum?

Brain Computer Interfaces are gaining the most momentum in the neurotechnology market. BCI funding rose from about $420M in 2024 to about $1.08B in 2025, and had already reached about $939M by early July 2026. BCI capital share rose from 31% in 2024 to 58% in 2025 and about 67% in year-to-date 2026.

The deal-count signal supports the same conclusion. BCI had 7 deals in 2024, 8 deals in 2025, and already 8 deals by early July 2026. That means BCI is not only receiving bigger checks; it is also sustaining deal flow.

Neuro Monitoring Tools are also gaining momentum, but from a very small base. The category had no qualifying deals in 2024, then 2 deals and $76M in 2025, and 1 deal and $54M by early July 2026. That is not yet a broad market, but the movement from zero to meaningful financing is a real signal.

Neuromodulation remains strong, but its momentum is steadier rather than explosive. It led deal count in 2024, 2025, and year-to-date 2026, but its capital share fell as BCI became more capital intensive. The practical reading is that neuromodulation is the repeatable clinical engine, while BCI is the category gaining the most investor excitement.

For deeper category-level benchmarks across BCI, neuromodulation, neurodiagnostics, EEG analytics, monitoring, and clinical software, see the deeper analysis of the neurotechnology market.

Which neurotechnology subcategories are losing momentum?

Neurodiagnostic Systems and Clinical Neurosoftware are losing momentum in relative terms, even though both remain investable. Neurodiagnostic Systems raised about $197M in 2024, helped by Ceribell’s IPO, then only about $33M in 2025 and about $11M by early July 2026.

The neurodiagnostic decline is partly a base-effect problem because 2024 included a large public-market financing. Still, the direction is clear: neurodiagnostics is not attracting the same scale of capital as BCI or neuromodulation.

Clinical Neurosoftware is even more financially peripheral. It raised about $42M in 2024, about $21M in 2025, and only about $1M by early July 2026. That suggests investors are not rewarding workflow-heavy or software-only neuro companies at the same scale as direct neural-interface or stimulation companies.

EEG Analytics Platforms are more nuanced. The category improved in 2025, reaching about $101M across 3 deals, but year-to-date 2026 had only 1 qualifying deal and $11M by early July. EEG analytics is investable when tied to proprietary neural data and clinical workflows, but it is not consistently funded at BCI scale.

This chart, featured in our neurotechnology market deck, shows why Neuropace is winning in neurotechnology

Which regions are gaining momentum in neurotechnology funding?

Asia-Pacific is gaining the most recent momentum in neurotechnology funding, while North America remains the dominant capital hub. Asia-Pacific raised about $451M across 6 deals by early July 2026, compared with only about $16M across 2 deals over the comparable period in 2025.

That is the clearest geographic acceleration in the market. The Asia-Pacific jump reflects large China and India-linked rounds, including BCI, neuro-monitoring, and non-invasive neuromodulation companies. The region is no longer only a small contributor to disclosed neurotechnology funding.

North America still leads by dollars and deal count. By early July 2026, North America had about $812M across 11 deals, equal to 58% of capital and 50% of deals. In 2025, North America captured about $1.63B, or 88% of all capital, across 22 deals.

Europe is also gaining versus the comparable 2025 period, but less dramatically than Asia-Pacific. Europe raised about $131M by early July 2026, compared with about $75M over the comparable 2025 period. The European signal is positive, but European round sizes remain smaller than North American and Asia-Pacific round sizes.

Which regions are losing momentum in neurotechnology funding?

North America is losing relative share in 2026, but it is not losing strategic importance. By early July 2026, North American capital was about $812M, down from about $962M over the comparable 2025 period, and North America’s capital share fell from about 91% to about 58%.

That relative decline should not be misread as weakness. North America still had the most capital and the most deals by early July 2026. The shift mainly reflects Asia-Pacific’s surge, not a collapse in North American neurotechnology funding.

Europe looked weaker in the full-year comparison, with capital falling from about $229M in 2024 to about $202M in 2025. But the current-year signal is better, with Europe rising from about $75M over the comparable 2025 period to about $131M by early July 2026.

The clearest regional absences are Latin America, the Middle East, and Africa. The Middle East had one large 2024 round through Insightec, but no qualifying 2025 or year-to-date 2026 capital in the supplied figures. Latin America and Africa show no qualifying disclosed equity deals across the reviewed periods.

Is the neurotechnology market becoming more global or more regionally concentrated?

The neurotechnology market is becoming more global in 2026, but it remains concentrated in a few regions. Full-year 2025 was highly North America-concentrated, with North America representing 71% of deals and 88% of capital. By early July 2026, North America had fallen to 50% of deals and 58% of capital, while Asia-Pacific had risen to 27% of deals and 32% of capital.

That is a meaningful broadening of the map. Asia-Pacific’s contribution is especially important because it is not limited to small rounds; it includes large financings in BCI and neuro-monitoring.

Still, the neurotechnology market is not globally distributed. The active map is North America, selected European clusters, and a rising Asia-Pacific corridor. Latin America, Africa, and most of the Middle East remain absent from qualifying disclosed equity activity in 2025 and 2026.

The best wording is that the neurotechnology market is becoming less North America-only, not fully global. Capital is expanding beyond the United States and Europe, but only into a limited number of technically dense and capital-rich ecosystems.

For the full regional funding view across North America, Europe, Asia-Pacific, and the inactive regions, see the market report covering neurotechnology geography.

This chart, featured in our neurotechnology market deck, shows how brain-computer interface progress has driven growth in the neurotechnology market over time

Is neurotechnology capital moving toward proven winners or new opportunities?

Neurotechnology capital is moving toward both proven winners and new opportunities, but the biggest sustained pool still favors proven or strategically exceptional companies. In full-year 2025, late-stage and growth equity capital represented about 80% of total funding, while first financings represented only about 13% of deals and 2% of capital.

That 2025 pattern is clearly a proven-winner pattern. Investors concentrated capital into companies that had already raised before, had clinical progress, had platform credibility, or had strategic value.

Year-to-date 2026 looks more open to new opportunities. First financings represented about 27% of deals and about 29% of capital by early July, compared with only about 6% of deals and 2% of capital over the comparable 2025 period. New entrants such as Merge Labs, Spiro Medical, Temple, neuropacs, Gestala, and BCI-Sonics show that investors are still willing to back new companies.

But “new opportunities” does not mean random experimentation. The new opportunities receiving serious capital tend to be platform-like, clinically specific, or strategically relevant. Investors are funding proven winners for clinical execution and new companies for interface-layer optionality.

Is the neurotechnology market becoming winner-takes-most?

Yes, the neurotechnology market is becoming winner-takes-most in capital allocation, even though deal count is not collapsing. The top 10 deals captured about 76% of capital in 2024, 81% in 2025, and about 90% by early July 2026.

The bottom-half metric confirms the same pattern. The bottom 50% of deals captured only about 11% of 2024 capital, 8% of 2025 capital, and 8% of year-to-date 2026 capital. Many companies are visible, but only a few companies define the funding total.

The largest rounds are structurally different from the rest of the market. In 2025, the largest deal was 32.5 times the median round. In year-to-date 2026, the largest deal was about 10 times the median round, which is less extreme but still highly unequal.

The neurotechnology market is not winner-takes-all because multiple categories and regions still receive funding. But it is winner-takes-most: a small number of companies with the strongest technical, clinical, regulatory, or strategic claims capture a disproportionate share of available capital.

Is the next wave of neurotechnology winners becoming visible?

Yes, the next wave of neurotechnology winners is becoming visible, but the visible winners are concentrated in a few subcategories. The strongest next-wave signals are in BCI, neuromodulation, neuro-monitoring, and neural data infrastructure.

BCI has the clearest next-wave signal. The category raised about $1.08B in 2025 and about $939M by early July 2026. Companies such as Neuralink, Synchron, Nudge, Science Corp, BrainCo, Merge Labs, Axoft, StairMed, and others show that investors are trying to identify category-defining neural-interface platforms before the market is fully commercialized.

In neuromodulation, the next-wave winners are more likely to look like clinically focused device companies than broad consumer platforms. Companies such as Saluda, SetPoint, Cognito Therapeutics, Spiro Medical, Neurent Medical, Nervonik, WISE, and Salvia BioElectronics show that investors reward disease-specific neuromodulation when the clinical pathway is concrete.

The next wave is less visible in Clinical Neurosoftware and Neurodiagnostic Systems. Those categories contain credible companies, but their capital share is much lower. The software and diagnostic winners will likely need proprietary neural data, regulatory-grade workflows, or a direct connection to therapy selection and monitoring.

For more context on the companies and subcategories shaping the next wave, see the full market view on neurotechnology winners.

As this chart shows, and as featured in our neurotechnology market deck, search interest in neurotechnology has been climbing steadily

Is the neurotechnology funding landscape fragmenting or consolidating?

The neurotechnology funding landscape is consolidating around a small number of capital-intensive themes, while the company universe remains fragmented. The themes attracting the most capital are BCI, neuromodulation, and, to a lesser degree, neuro-monitoring and EEG data infrastructure.

The consolidation signal is strongest in capital concentration. The top 10 deals captured about 81% of 2025 capital and about 90% of year-to-date 2026 capital. BCI alone captured 58% of 2025 capital and 67% of year-to-date 2026 capital.

The fragmentation signal is visible in technology diversity and investor repetition. Funded companies span implantable BCI, ultrasound BCI, EEG analytics, DBS, spinal stimulation, sensory neuromodulation, peripheral nerve stimulation, neuro-monitoring wearables, eye-tracking diagnostics, and clinical neurosoftware. Very few investors appear in more than one qualifying deal per period.

The best interpretation is that funding is consolidating, but technology remains fragmented. Investors are concentrating capital into perceived leaders, but the industry has not converged on a single winning modality, indication, or business model.

Where is investor attention shifting in neurotechnology?

Investor attention in the neurotechnology market is shifting toward direct nervous-system interfaces, platform-scale BCI, and clinically specific neuromodulation. BCI’s capital share rose from 31% in 2024 to 58% in 2025 and about 67% by early July 2026, which is the clearest sign of where the largest checks are moving.

Investor attention is also shifting toward strategic and crossover-backed rounds. The presence of OpenAI, Bain Capital, Alibaba, Tencent, Peak XV, Steadview, Khosla, Lightspeed, Morningside, Samsung Next, and other strategic or crossover investors suggests that neurotechnology is being evaluated as frontier interface and data infrastructure, not only as medtech.

At the same time, investor attention remains durable in disease-specific neuromodulation. Neuromodulation led deal count in each reviewed period, with 17 deals in 2024, 13 in 2025, and 10 already by early July 2026. The difference is that neuromodulation is funded more like a repeatable clinical-device category, while BCI is funded more like a potential platform market.

Investor attention is shifting away from generic neuro-adjacent software. Clinical Neurosoftware and Neurodiagnostic Systems remain legitimate categories, but they are not capturing the largest capital pools. The market is rewarding companies closest to the nervous-system signal itself: measuring it, decoding it, stimulating it, closing the loop around it, or turning it into a defensible data layer.

For ongoing tracking of where investor attention is moving across the neurotechnology market, see the neurotechnology market report.

This chart, featured in our neurotechnology market deck, shows how brain sensing wearable technology has evolved over time

Who is the author of this content?

NEW MARKET PITCH TEAM

We track new markets so founders and investors can move faster

We build living “market pitch” documents for emerging markets: from AI to synthetic biology and new proteins. Instead of digging through outdated PDFs, random blog posts, and hallucinated LLM answers, our clients get a clean, visual, always-updated view of what’s really happening. We map the key players, deals, regulations, metrics and signals that matter so you can decide faster whether a market is worth your time. Want to know more? Check out our about page.